arrow
J

James O. Lindsay

Barts and the London School of Medicine
H指数:71
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension study

risankizumab在中度至重度活动性克罗恩病患者中的疗效和安全性: 序列开放标签扩展研究的中期结果

2025-12-010
OA
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease

评估PredictSURE IBD检测在跨国炎症性肠病患者队列中的应用

2025-07-110
OAAI
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment

扩展性瑞萨克珠单抗治疗对诱导治疗未达到临床应答的克罗恩病患者的影响

2025-02-030
OAAI
Trans-continental analysis of determinants of response to COVID-19 vaccination in 2268 patients with Inflammatory Bowel Disease
2025-01-220
PRE
Impact of pain, fatigue and bowel incontinence on the quality of life of people living with inflammatory bowel disease: A UK cross-sectional survey

疼痛、乏力和大便失禁对炎症性肠病患者生活质量的影响: 一项英国横断面调查

2024-10-195
OAAI
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure

Upadacitinib在克罗恩病中实现了临床和内镜结果,无论先前的生物暴露如何

2024-10-016
OAAI
Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study

奥扎尼妥(Ozanimod)连续治疗5年后的持续疗效与安全性:True North开放标签扩展研究的期中分析

2024-10-010
PRE
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
2024-07-1810
PRE
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
2024-05-0143
OAAI
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial

自体造血干细胞移植联合低剂量环磷酰胺动员和低强度预处理与标准治疗难治性克罗恩病的安全性和有效性 (ASTIClite): 一项开放标签、多中心、随机对照试验

2024-04-017
OAAI